KR900700108A - 수크랄페이트의 용도 - Google Patents

수크랄페이트의 용도

Info

Publication number
KR900700108A
KR900700108A KR1019890701561A KR890701561A KR900700108A KR 900700108 A KR900700108 A KR 900700108A KR 1019890701561 A KR1019890701561 A KR 1019890701561A KR 890701561 A KR890701561 A KR 890701561A KR 900700108 A KR900700108 A KR 900700108A
Authority
KR
South Korea
Prior art keywords
skin
sucralate
less
weight
treatment
Prior art date
Application number
KR1019890701561A
Other languages
English (en)
Inventor
바-샬롬 다니엘
부크 닐스
Original Assignee
바-샬롬 다니엘
부크 닐스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK674087A external-priority patent/DK674087D0/da
Application filed by 바-샬롬 다니엘, 부크 닐스 filed Critical 바-샬롬 다니엘
Publication of KR900700108A publication Critical patent/KR900700108A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/58—Metal complex; Coordination compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Polymerisation Methods In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

수크랄페이트의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. 염증, 또는 감염 발현의 예방 또는 치료용, 조직 재생과정의 조절 또는 촉진용, 면역반응 조절용, 비낭형 예비악성 또는 악성 질환의 치료 또는 예방용, 또는 피부, 연결조직, 또는 비위장, 비구강 점막의 자극, 화상 또는 궤양화의 예방 또는 치료용의, 동물이나 인간의 체강내막을 비롯한 피부 또는 비위장, 비구강 점막표면에 국소 적용하기 위한 의약의 제조용; 또는 피부, 연결조직, 또는 비구강 점막의 열상, 병변, 또는 외상치료용, 또는 피부, 연결조직, 또는 비부강 점막 노화의 예방 또는 치료용의 동물이나 인간의 피부 또는 모든 비구강 점막표면에 국소적용하기 위한 의약의 제조용으로서의 수크랄페이트의 용도.
  2. 제1항에 있어서 상기 의약이 피부 또는 점막의 국부사용에 적합한 형태, 예를들어, 분말, 페이스트, 연고, 로션, 겔, 크림, 고약, 유제, 현탁액, 스프레이, 스폰지, 띠, 반창고, 패드, 붕대 또는 문합술판인 용도.
  3. 제1항 또는 제2항에 있어서, 상기의 의약이 0.001-99%, 전형적으로는 0.01-75%, 보다 전형적으로는 0.1-21%, 특히 1-10%, 이를테면 그 제제의 2-6 중량%인 양으로 수크랄페이트가 함유된 국부용 제제형태인 용도.
  4. 제1항 내지 제3항 중의 어느 한 항에 있어서, 수크랄페이트가 약 200㎛ 이하, 이를테면 100㎛ 이하 예를 들어 50㎛ 이하, 이를테면 20㎛ 이하, 예를들어 10㎛ 이하, 이를테면 1-5㎛ 이하인 입도의 입자형태인 용도.
  5. 제1항 내지 제4항 중의 어느 한 항에 있어서, 국부용 제제가 1일 1-10회 사용되도록 의도된 용도.
  6. 제1항에 있어서, 점막이 질, 코 또는 눈의 점막인 용도.
  7. 제5항에 있어서, 수크랄페이트가 비황산화 다당류, 예를들어 히아루론산인 용도.
  8. 제6항 또는 제7항에 있어서, 상기 의약이 그 제제의 중량으로 계산하여, 수크랄페이트 0.1-99 중량% 바람직하게는 1-75 중량%, 보다 바람직하게는 1-30 중량%를 함유하는 국부용 제제 형태인 용도.
  9. 제8항에 있어서, 상기 의약이 그 제제의 중량으로 계산하여, 수크랄페이트 1-10 중량%를 함유하는 국부용 제제 형태인 용도.
  10. 제8항 또는 제9항에 있어서, 상기 의약이 질좌약, 탐폰, 질 세정용 현탁액, 질 알약 또는 정제, 질 크림 또는 겔 연고, 코 삽입제, 코 점적약 또는 스프레이, 코 연고 또는 겔, 눈의 점적약, 눈의 연고, 눈의 겔, 또는 삽입제와 같은 질, 코 또는 눈의 사용에 적합한 형태인 용도.
  11. 약제 제제, 구체적으로는 피부 또는 비낭성, 비위장, 비구강점막, 표면에의 국부 적용을 위한 것으로서, 스크랄페이트가 약리학적으로 허용되는 담체 또는 부형제와 함께 함유된 약제 제제.
  12. 제11항에 있어서, 코, 호흡기관, 눈, 귀, 질, 외음부의 점막, 입술 및 항문부위와 같은 경계부위, 피부에 국부 적용되도록 의도된 약제 제제.
  13. 제11항 또는 제12항에 있어서, 분말, 페이스트, 연고, 로션, 겔, 크림, 고약, 유제, 현탁액, 스프레이, 스폰지, 띠, 반창고, 패드, 붕대 또는 문합술판의 형태인 약제 제제.
  14. 제11항 내지 제13항 중의 어느 한 항에 있어서, 제제의 0.001-99 중량%, 전형적으로는 0.01-75 중량%, 보다 전형적으로는 0.1-20%, 특히 1-10 중량%의 양으로 수크랄페이트를 함유한 약제 제제.
  15. 제11항 내지 제14항 중의 어느 한 항에 있어서, 수크랄페이트가 약 200㎛ 이하, 이를테면 100㎛ 이하, 예를들어 50㎛ 이하, 이를테면 20㎛ 이하, 예를들어 10㎛ 이하, 이를테면 약 1-5㎛ 이하인 입도의 입자형태인 약제 제제.
  16. 피부, 점막 또는 조직에 수크랄페이트의 치료학적 또는 예방학적 유효량을 적용하는 것으로 이루어지는, 조직재생 과정의 조절 또는 촉진; 면역반응의 조절; 비낭형 예비악성 또는 악성 질환의 예방 또는 치료; 피부, 연결조직, 또는 비위장, 비구강 점막의 자극, 화상 또는 궤양화의 예방 또는 치료; 피부, 연결조직, 비구강점막의 열상, 병변 또는 외상의 뇌료, 또는 피부, 연결조직, 점막 노화의 예방 또는 치료를 위한 인간이나 동물의 체강을 비롯한 피부, 비위장, 비구강 점막표면의 염증이나 감염 발현의 예방 또는 치료방법.
  17. 제16항에 있어서, 수크랄페이트를 비황산화 다당류, 예를들어 히아루론산과 배합하는 것을 특징으로 하는 방법.
  18. 제16항 또는 제17항에 있어서, 수크랄페이트를 분말, 페이스트, 연고, 로션, 겔, 크림, 고약, 유제, 현탁액, 스프레이, 스폰지, 띠, 반창고, 패드, 붕대 또는 문합술판으로써 사용하는 것을 특징으로 하는 방법.
  19. 제16항 내지 제18항 중의 어느 한 항에 있어서, 수크랄페이트를 1일 1-10회 사용하는 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890701561A 1987-12-21 1988-12-21 수크랄페이트의 용도 KR900700108A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK674087A DK674087D0 (da) 1987-12-21 1987-12-21 Saarbehandlingsmiddel
DK6740/87 1988-09-09
DK5054/88 1988-09-09
DK505488A DK505488D0 (da) 1987-12-21 1988-09-09 Middel og anvendelse af samme
PCT/DK1988/000216 WO1989005645A1 (en) 1987-12-21 1988-12-21 Use of sucralfate

Publications (1)

Publication Number Publication Date
KR900700108A true KR900700108A (ko) 1990-08-11

Family

ID=26067713

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019890701561A KR900700108A (ko) 1987-12-21 1988-12-21 수크랄페이트의 용도
KR1019890701562A KR930003117B1 (ko) 1987-12-21 1988-12-21 황산화 이당류를 활성성분으로 함유하는 염증예방 또는 치료용 제약조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019890701562A KR930003117B1 (ko) 1987-12-21 1988-12-21 황산화 이당류를 활성성분으로 함유하는 염증예방 또는 치료용 제약조성물

Country Status (9)

Country Link
EP (3) EP0640346B1 (ko)
JP (2) JPH04500797A (ko)
KR (2) KR900700108A (ko)
AT (2) ATE119778T1 (ko)
AU (2) AU631529B2 (ko)
DE (2) DE3853365T2 (ko)
DK (4) DK505488D0 (ko)
HK (1) HK56396A (ko)
WO (2) WO1989005646A1 (ko)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK674087D0 (da) * 1987-12-21 1987-12-21 Bar Shalom Daniel Saarbehandlingsmiddel
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5618798A (en) * 1989-04-20 1997-04-08 Bar-Shalom; Daniel Use of sucralfate to treat baldness
IT1230157B (it) * 1989-06-16 1991-10-14 Lisapharma Spa Uso di sucralfato gel umido per il trattamento di ulcere del derma e come veicolo di farmaci ad attivita' topica
IE903302A1 (en) * 1989-09-15 1991-04-10 Pehrom Pharmaceutical Corp Topical preparation for treatment of aphthous ulcers and¹other lesions
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
ES2168251T3 (es) * 1990-08-31 2002-06-16 Chugai Pharmaceutical Co Ltd Produccion de una solucion de base de sucralfato en suspension en agua.
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
EP0509120B1 (en) * 1991-04-18 1996-07-17 LABORATORI BALDACCI Spa Topical use of glycosaminoglycans in the prevention and treatment of diseases affecting the cervical vaginal tract
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
IT1251151B (it) * 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
US6147059A (en) * 1992-02-20 2000-11-14 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
CA2110176A1 (en) * 1992-03-28 1993-10-14 Akira Yanagawa Topical preparation for healing wounds of the skin
US6750207B1 (en) * 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
DK86492D0 (da) * 1992-06-30 1992-06-30 Bukh Meditec Laegemiddel
AU6362594A (en) * 1993-03-10 1994-09-26 Miles Inc. Hyaluronic acid used as a cancer treatment
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
EP1060750B1 (en) * 1993-03-29 2005-12-07 Queen's University At Kingston Propane-1,3-disulfonic acid and its pharmaceutically acceptable salts for treating amyloidosis
US5434144A (en) * 1994-03-04 1995-07-18 The Procter & Gamble Company Methods of using cyclic polyanionic polyol derivatives for regulating skin wrinkles
AU703926B2 (en) * 1994-03-28 1999-04-01 Trustees Of Columbia University In The City Of New York, The Composition for inactivating irritants in fluids
EP1110540A1 (en) * 1994-04-26 2001-06-27 Chugai Seiyaku Kabushiki Kaisha Melt granulated sucralfate preparations
SE9401826D0 (sv) * 1994-05-27 1994-05-27 Pharmacia Ab Anti-Helicobacter pyroli substance
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
EP0808629A4 (en) * 1995-02-02 1998-03-04 Chugai Pharmaceutical Co Ltd PREPARATION OF SUCRALFATE
WO1996024362A1 (fr) * 1995-02-07 1996-08-15 Shiseido Company, Ltd. Agents anti-inflammatoires
US6537977B1 (en) * 1995-09-19 2003-03-25 Seikagaku Corporation Anti-inflammatory agent
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
US5837266A (en) * 1996-04-30 1998-11-17 Hydromer, Inc. Composition, barrier film, and method for preventing contact dermatitis
CH690719A5 (it) * 1996-08-19 2000-12-29 Rotta Res B V Amsterdam Swiss Procedimento per la preparazione di sali misti della glucosamina.
WO1998017282A1 (en) * 1996-10-23 1998-04-30 Vertex Pharmaceuticals Incorporated Methods of using sucrose octasulfate to treat or prevent enveloped virus infection
GB9625193D0 (en) 1996-12-04 1997-01-22 Ml Lab Plc Treatment of highly vascular tumours
ATE304362T1 (de) * 1997-11-24 2005-09-15 Zhongming Zeng Pharmazeutische zusammensetzung zur stimulierung des wachstums von gram-positiven bazillen und zur erhöhung der azidität der vagina und ihre verwendung
FI974321A0 (fi) 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
WO1999043333A1 (en) * 1998-02-27 1999-09-02 The Althexis Company Therapeutic and prophylactic uses of negatively charged substituted disaccharides
US5902800A (en) * 1998-03-27 1999-05-11 Glenpharma Dextran formulations and method for treatment of inflammatory joint disorders
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
BR9806540C1 (pt) * 1998-06-09 2001-05-08 Akira Yoshitome Produto farmacêutico para tratamento de hemofilia e de bronquite asmática
DE69926770T2 (de) 1998-10-05 2006-06-29 Kabushiki Kaisha Yakult Honsha Antibakterielle mittel und ein herstellungsverfahren dafür
AU2007200916B2 (en) * 1998-10-05 2009-09-17 Kabushiki Kaisha Yakult Honsha Antibacterial agents and process for producing the same
CA2356637C (en) * 1998-12-22 2011-09-13 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
US6964949B2 (en) 2000-05-24 2005-11-15 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
BRPI0101486B1 (pt) * 2001-04-17 2017-09-19 Cristália Produtos Químicos Farmacêuticos Ltda. Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
US7285536B2 (en) 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
AU2002366763A1 (en) * 2001-12-13 2003-07-09 Dia Pharmaceutical Co., Ltd. Gel compositions for external use, pad materials and pad materials to be packed in blister containers
US7879365B2 (en) 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
AU2003216213B2 (en) 2002-02-07 2008-10-02 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
US7265097B2 (en) 2002-08-20 2007-09-04 Chitogenics, Inc. Methods of drug delivery using sulphated chitinous polymers
US20060234977A1 (en) * 2003-01-23 2006-10-19 Gina Wenham Antiviral compostion comprising a sulphated glucose polymer and a bacteriostatic agent
BRPI0412675A (pt) 2003-07-17 2006-10-03 Univ Columbia composições antimicrobianas contendo combinações sinergìsticas de compostos de amÈnio quaternário e óleos essenciais e/ou constituintes
US20080249165A1 (en) * 2004-08-05 2008-10-09 Ivax Drug Research Institute Ltd. Glycosides and Salts Thereof
US7902158B2 (en) 2004-08-05 2011-03-08 Ivax Drug Research Ltd. Polysulfated glycosides and salts thereof
US20090215717A1 (en) * 2004-08-05 2009-08-27 Ivax Drug Research Institute Ltd. Sulfated oligosaccharides
CA2900876A1 (en) 2004-12-22 2006-08-17 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
ES2313267T3 (es) * 2005-09-16 2009-03-01 Italfar Societa A Responsabilita Limitata Composicion farmaceutica de cicatrizacion de heridas que comprende sucralfato, glicina, acetato de aluminio y vitaminas.
MX2008008213A (es) 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
KR20080025900A (ko) * 2006-09-19 2008-03-24 (주) 서울바이오메드 글루코사민 또는 글루코사민 유도체를 포함하는 알레르기성결막염 치료용 조성물 및 이를 사용하여 알레르기성결막염을 치료하는 방법
FI3851447T3 (fi) 2006-10-12 2023-11-15 Bellus Health Inc Menetelmiä, yhdisteitä, koostumuksia ja vehikkeleitä 3-amino-1-propaanisulfonihapon vapauttamiseksi
GB0622688D0 (en) 2006-11-14 2006-12-27 Diosamine Dev Corp Novel compounds
GB2450087A (en) * 2007-06-11 2008-12-17 Diosamine Dev Corp Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases
WO2010033408A1 (en) 2008-09-17 2010-03-25 Mcgrath Patrick D Antimicrobial sucralfate paste methods and compositions
PL2679278T3 (pl) * 2008-11-20 2018-02-28 Laboratori Derivati Organici S.P.A. Kompozycje dermatologiczne zawierające siarczan heparanu
FR2953522B1 (fr) * 2009-12-07 2012-03-09 Fabre Pierre Dermo Cosmetique Sucrose octasulfates de zinc, leur preparation et leurs applications pharmaceutiques et cosmetiques
FR2956322A1 (fr) * 2010-02-17 2011-08-19 Urgo Lab Utilisation d'oligosaccharides polysulfates synthetiques comme agents de detersion d'une plaie.
KR20130018739A (ko) 2010-03-03 2013-02-25 네오큐티스 에스아 항균 펩티드 격리 화합물을 사용한 피부 질환 및 장애의 치료를 위한 조성물 및 방법
EP2646037B1 (en) * 2010-12-01 2019-01-09 The Australian National University use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis.
ITMI20110033A1 (it) * 2011-01-17 2012-07-18 Biofarmitalia Spa Composizione terapeutica mucoadesiva a base di acido ialuronico per la prevenzione e terapia di lesioni epiteliali, delle mucose del corpo umano
FR2975994B1 (fr) * 2011-05-31 2015-03-06 Fabre Pierre Dermo Cosmetique Sucroses octasulfates de calcium, leur preparation et leurs applications pharmaceutiques et cosmetiques
FR2975993B1 (fr) * 2011-05-31 2013-06-28 Fabre Pierre Dermo Cosmetique Sucroses octasulfates de magnesium, leur preparation et leurs applications pharmaceutiques et cosmetiques
FR2991876B1 (fr) * 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
FR2993182B1 (fr) 2012-07-13 2014-10-17 Urgo Lab Pansement a liberation prolongee d'actifs
US10716802B2 (en) 2013-03-15 2020-07-21 The Brigham And Women's Hospital, Inc. Compounds to modulate intestinal absorption of nutrients
KR101649201B1 (ko) * 2014-01-22 2016-08-18 대구가톨릭대학교산학협력단 오만둥이 유래 황산다당을 유효성분으로 함유하는 피부 미백 및 주름 개선용 화장료 조성물
US10973846B2 (en) 2015-09-24 2021-04-13 The Brigham And Women's Hospital, Inc. Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients
FR3043556B1 (fr) * 2015-11-17 2020-01-10 Urgo Recherche Innovation Et Developpement Utilisation de composes oligosaccharidiques pour activer l'angiogenese
FR3044555B1 (fr) 2015-12-07 2020-03-06 Centre National De La Recherche Scientifique - Cnrs - Film comprenant un oligosaccharide polysulfate et un polycation et son procede de fabrication
FR3060392B1 (fr) * 2016-12-19 2019-07-12 Urgo Recherche Innovation Et Developpement Utilisation de composes oligosaccharidiques pour activer l'epidermisation
IT201700047632A1 (it) * 2017-05-03 2018-11-03 Ricerfarma Srl Composizioni topiche per mantenere e ripristinare l'omeostasi idrica della pelle

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486416A (en) * 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
FR2503563A1 (fr) * 1981-04-09 1982-10-15 Pos Lab Composition pour collyre a base de sulfate de chondroitine a
DE3131811A1 (de) * 1981-08-12 1983-04-21 Serapharm - Michael Stroetmann, 4400 Münster Heparinsalbe zur percutanen behandlung von thrombophlebitiden oder varizen
IT1189298B (it) * 1982-06-18 1988-02-04 Manetti & Roberts Italo Brit Procedimento per produrre i glicosa minoglicani dermatansolfato ed eparan-solfato sostanzialmente puri e loro impiego farmaceutico
JPS5978116A (ja) * 1982-10-27 1984-05-04 Chugai Pharmaceut Co Ltd スクラルフェ−ト製剤
US4640912A (en) * 1983-06-09 1987-02-03 Hausman Marvin S Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans
DE3323389A1 (de) * 1983-06-29 1985-01-10 B. Braun Melsungen Ag, 3508 Melsungen Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
CA1218601A (en) * 1983-09-02 1987-03-03 Angel B. Casillan Sucralfate suspension
AU607690B2 (en) * 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
DK164199C (da) * 1986-05-16 1992-10-19 Chugai Pharmaceutical Co Ltd Sucralfatpraeparat til anvendelse paa oesophagus mucosa
EP0254845A3 (en) * 1986-06-10 1989-04-19 Lescarden Inc. Immune stimulation with chondroitin sulfate
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme

Also Published As

Publication number Publication date
AU2914689A (en) 1989-07-19
KR930003117B1 (ko) 1993-04-19
AU631529B2 (en) 1992-12-03
EP0420849A1 (en) 1991-04-10
DE3853365T2 (de) 1995-07-27
EP0394333B1 (en) 1995-03-15
DK165357B (da) 1992-11-16
JPH04500797A (ja) 1992-02-13
DE3856442T2 (de) 2001-05-10
DK5792D0 (da) 1992-01-17
WO1989005645A1 (en) 1989-06-29
DK151590A (da) 1990-08-14
DK151590D0 (da) 1990-06-21
KR900700109A (ko) 1990-08-11
DK151690A (da) 1990-08-15
DE3856442D1 (de) 2000-12-21
DK165357C (da) 1993-04-05
WO1989005646A1 (en) 1989-06-29
DK151690D0 (da) 1990-06-21
HK56396A (en) 1996-04-03
DK169018B1 (da) 1994-08-01
AU2914589A (en) 1989-07-19
DK5792A (da) 1992-01-17
EP0394333A1 (en) 1990-10-31
DK505488D0 (da) 1988-09-09
ATE119778T1 (de) 1995-04-15
JPH04500798A (ja) 1992-02-13
EP0640346A1 (en) 1995-03-01
ATE197546T1 (de) 2000-12-15
DE3853365D1 (de) 1995-04-20
EP0640346B1 (en) 2000-11-15
JPH0739347B2 (ja) 1995-05-01

Similar Documents

Publication Publication Date Title
KR900700108A (ko) 수크랄페이트의 용도
Davis et al. Wound healing. Oral and topical activity of Aloe vera
JP2008513438A (ja) 皮膚の状態、障害または疾患の処置のための胎児皮膚細胞タンパク質組成物、ならびにその作製法および使用法
EP0281812A1 (en) Composition for treatment of acne
US4107330A (en) Topical application of thioglycolic acid in the treatment of acne
US11696907B2 (en) Wound healing composition
JPH0825908B2 (ja) 局所活性を有する医薬品用又は化粧品用の担持剤としてのスクラルフェート湿潤ゲルの用途
JPS5877824A (ja) インターフェロンを含む組成物
CN115282072A (zh) 一种含有锌和硅生物活性离子无机材料的祛痤疮复合材料及应用
CA2020199A1 (en) Uses of sulphated sugars
RU2293557C2 (ru) Средство для местного использования при лечении заболевания кожи и слизистых
RU2644255C1 (ru) Ранозаживляющее средство
US8900601B2 (en) Permeable mixtures, methods and compositions for the skin
RU2258516C1 (ru) Способ лечения красного плоского лишая
CA2020200A1 (en) Use of sucralfate
RU2725634C1 (ru) Комплексное соединение цинка с n-изопропенилимидазолом как ранозаживляющее средство
EP0078533B1 (en) Medicinal composition for treating skin disorders
PT1351694E (pt) Favorecimento da reconstrução celular e/ou da diferenciação celular com açúcar não metabolizável e um absorvente polimérico
Kalz et al. AUREOMYCIN FILM IN CUTANEOUS ERUPTIONS
KR20040087006A (ko) 수용성 고분자를 이용한 시이트형 하이드로겔 팩제 및 그제조방법
CARRICK Cutaneous Cryptococcosis: Report of a Case Treated With Potassium Iodide and X-Ray Therapy
WO2000024370A1 (en) Dermatologic gels for the treatment of acne vulgaris and herpes simplex containing methenamine
RU2271218C2 (ru) Способ местного лечения папилломавирусной инфекции урогенитального тракта у женщин
JPS5896017A (ja) 「あ」瘡および口周囲皮膚炎の処置方法
CN115429841A (zh) 一种面部冷敷凝胶

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application